European Journal of Clinical Pharmacology

, Volume 66, Issue 6, pp 619–625 | Cite as

Rofecoxib, but not celecoxib, increases the risk of thromboembolic cardiovascular events in young adults—a nationwide registry-based study

  • Bjorn Gudbjornsson
  • Sigurdur B. Thorsteinsson
  • Helgi Sigvaldason
  • Rannveig Einarsdottir
  • Magnus Johannsson
  • Helga Zoega
  • Matthias Halldorsson
  • Gudmundur Thorgeirsson
Pharmacoepidemiology and Prescription

Abstract

Purpose

To examine the risk of thromboembolic cardiovascular events in users of coxibs and NSAIDs in a nationwide cohort.

Methods

Data were synchronised from three nationwide databases, the Icelandic Medicines Registry (IMR), The Icelandic National Patient Registry (INPR) and the Registry for Causes of Death at Statistics Iceland (RCD), for prescriptions for NSAIDs or coxibs with respect to hospitalisation for unstable angina pectoris, myocardial infarction and cerebral infarction over a 3-year period. The Cox proportional hazards model and Poisson regression were used to analyse the data.

Results

A total of 108,700 individuals received prescriptions for NSAIDs or coxibs (ATC code M01A), of whom 78,539 received one drug only (163,406 person-years). Among those receiving only one drug 426 individuals were discharged from hospital with endpoint diagnoses. In comparison to diclofenac, the incidence ratios, adjusted for age and gender, were significantly higher for cerebral infarction (2.13; 95% CI 1.54–2.97; P < 0.001), for myocardial infarction (1.77; 95% CI 1.34–2.32; P < 0.001) and for unstable angina pectoris (1.52; 95% CI 1.01–2.30; P = 0.047) for patients who used rofecoxib. For naproxen users, the incidence ratio was 1.46 for myocardial infarction (95% CI 1.03–2.07; P = 0.03), but was reduced in ibuprofen users (0.63; 95% CI 0.40–1.00; P = 0.05). The youngest users of rofecoxib (≤39 years) had the highest hazard ratio (HR) for cardiovascular events (8.34; P < 0.001), while those ≥60 years had a lower but still significantly elevated HR (1.35; P = 0.001).

Conclusion

This Icelandic nationwide registry-based study amounting to 163,406 patient-years showed increased risk of cardiovascular events, i.e. cerebral infarction, myocardial infarction and unstable angina pectoris, among rofecoxib and naproxen users in comparison to diclofenac users. The added risk was most pronounced in young adults using rofecoxib.

Keywords

COX-2 specific inhibitors Nationwide NSAID Pharmacoepidemiology Registry 

References

  1. 1.
    Rosen GD, Birkenmeier TM, Raz A, Holtzam MJ (1989) Identification of a cyclooxygenase-related gene and its potential role in prostaglandin formation. Biochem Biophys Res Commun 164:1358–1365CrossRefPubMedGoogle Scholar
  2. 2.
    Raz A, Wyche A, Needleman P (1989) Temporal and pharmacological division of fibroblast cyclooxygenase expression into transcriptional and translational phases. Proc Natl Acad Sci USA 86:1657–1661CrossRefPubMedGoogle Scholar
  3. 3.
    Han JW, Sadowski H, Young DA, Macara IG (1990) Persistent induction of cyclooxygenase in p60v-src-transformed 3T3 fibroblasts. Proc Natl Acad Sci USA 87:3373–3377CrossRefPubMedGoogle Scholar
  4. 4.
    Vane JR (1971) Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 231:232–235PubMedGoogle Scholar
  5. 5.
    Xie WL, Chipman JG, Robertson DL, Erikson RL, Simmons DL (1991) Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci USA 88:2692–2696CrossRefPubMedGoogle Scholar
  6. 6.
    Kujubu DA, Fletcher BS, Varnum BC, Lim RW, Herschman HR (1991) TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J Biol Chem 266:12866–12872PubMedGoogle Scholar
  7. 7.
    Simon LS, Lanza FL, Lipsky PE et al (1998) Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects. Arthritis Rheum 41:1591–1602CrossRefPubMedGoogle Scholar
  8. 8.
    Ehrich EW, Dallob A, De Lepeleire I et al (1999) Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model. Clin Pharmacol Ther 65:336–347CrossRefPubMedGoogle Scholar
  9. 9.
    Baron JA, Sandler RS, Bresalier RS et al (2008) Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial. Lancet 372:1756–1764CrossRefPubMedGoogle Scholar
  10. 10.
    Solomon SD, McMurray JJ, Pfeffer MA et al (2005) Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352:1071–1080CrossRefPubMedGoogle Scholar
  11. 11.
    Bertagnolli MM, Eagle CJ, Zauber AG et al (2006) Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 355:873–884CrossRefPubMedGoogle Scholar
  12. 12.
    Research Group ADAPT (2006) Cardiovascular and cerebrovascular events in the randomized, controlled Alzheimer’s Disease Anti-Inflammatory Prevention Trial (ADAPT). PLoS Clin Trials 1(7):e33CrossRefGoogle Scholar
  13. 13.
    Aisen PS, Schafer KA, Grundman M et al (2003) Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA 289:2819–2826CrossRefPubMedGoogle Scholar
  14. 14.
    Jüni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, Egger M (2004) Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet 364:2021–2029CrossRefPubMedGoogle Scholar
  15. 15.
    Hippisley-Cox J, Coupland C (2005) Risk of myocardial infarction in patients taking cyclooxygenase inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ 330:1366–1372CrossRefPubMedGoogle Scholar
  16. 16.
    Graham DJ, Campen D, Hui R et al (2005) Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclooxygenase-2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 365:475–481PubMedGoogle Scholar
  17. 17.
    Solomon DH, Schneeweiss S, Glynn RJ et al (2004) Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation 109:2068–2073CrossRefPubMedGoogle Scholar
  18. 18.
    Fosbøl EL, Gislason GH, Jacobsen S et al (2009) Risk of myocardial infarction and death associated with the use of nonsteroidal anti-inflammatory drugs (NSAIDs) among healthy individuals: a nationwide cohort study. Clin Pharmacol Ther 85:190–197CrossRefPubMedGoogle Scholar
  19. 19.
    Statistics Iceland (2009) Population by sex and age. www.statice.is
  20. 20.
    Gebski V, Leung O, McNeil D, Lunn D (1992) Statistical package for interactive data analysis (SPIDA), version 6. Macquarie University, SydneyGoogle Scholar
  21. 21.
    Haag MD, Bos MJ, Hofman A, Koudstaal PJ, Breteler MM, Stricker BH (2008) Cyclooxygenase selectivity of nonsteroidal anti-inflammatory drugs and risk of stroke. Arch Intern Med 168:1219–1224CrossRefPubMedGoogle Scholar
  22. 22.
    Roumie CL, Mitchel EF Jr, Kaltenbach L, Arbogast PG, Gideon P, Griffin MR (2008) Nonaspirin NSAIDs, cyclooxygenase 2 inhibitors, and the risk for stroke. Stroke 39:2037–2045CrossRefPubMedGoogle Scholar
  23. 23.
    Johnsen SP, Larsson H, Tarone RE et al (2005) Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study. Arch Intern Med 165:978–984CrossRefPubMedGoogle Scholar
  24. 24.
    Finckh A, Aronson MD (2005) Cardiovascular risks of cyclo-oxygenase-2 inhibitors: where do we stand now? Ann Intern Med 142:157–164Google Scholar
  25. 25.
    Varas-Lorenzo C, Castellsague J, Stang MR, Perez-Gutthann S, Aguado J, Rodriguez LA (2009) The use of selective cyclooxygenase-2 inhibitors and the risk of acute myocardial infarction in Saskatchewan, Canada. Pharmacoepidemiol Drug Saf 18:1016–1025CrossRefPubMedGoogle Scholar
  26. 26.
    McGettigan P, Henry D (2006) Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 296:1633–1644CrossRefPubMedGoogle Scholar
  27. 27.
    Gislason GH, Jacobsen S, Rasmussen JN et al (2006) Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction. Circulation 113:2906–2913CrossRefPubMedGoogle Scholar
  28. 28.
    Goodson NJ, Brookhart AM, Symmons DP, Silman AJ, Solomon DH (2009) Non-steroidal anti-inflammatory drug use does not appear to be associated with increased cardiovascular mortality in patients with inflammatory polyarthritis: results from a primary care based inception cohort of patients. Ann Rheum Dis 68:367–372CrossRefPubMedGoogle Scholar
  29. 29.
    Funk CD, FitzGerald GA (2007) COX-2 inhibitors and cardiovascular risk. J Cardiovasc Pharmacol 50:470–479CrossRefPubMedGoogle Scholar
  30. 30.
    Bunimov N, Laneuville O (2008) Cyclooxygenase inhibitors: instrumental drugs to understand cardiovascular homeostasis and arterial thrombosis. Cardiovasc Hematol Disord Drug Targets 8:268–277CrossRefPubMedGoogle Scholar
  31. 31.
    Patrono C, Patrignani P, Garcia Rodriguez L (2001) Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs. J Clin Invest 108:7–13PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Bjorn Gudbjornsson
    • 1
    • 5
  • Sigurdur B. Thorsteinsson
    • 2
  • Helgi Sigvaldason
    • 4
  • Rannveig Einarsdottir
    • 2
  • Magnus Johannsson
    • 6
  • Helga Zoega
    • 4
    • 7
  • Matthias Halldorsson
    • 4
  • Gudmundur Thorgeirsson
    • 3
    • 5
  1. 1.Centre for Rheumatology ResearchLandspitali University HospitalReykjavikIceland
  2. 2.Division of Pharmaceutical ServicesLandspitali University HospitalReykjavikIceland
  3. 3.Department of MedicineLandspitali University HospitalReykjavikIceland
  4. 4.Directorate of HealthReykjavikIceland
  5. 5.Faculty of MedicineUniversity of IcelandReykjavikIceland
  6. 6.Department of PharmacologyUniversity of IcelandReykjavikIceland
  7. 7.Faculty of Pharmaceutical SciencesUniversity of IcelandReykjavikIceland

Personalised recommendations